Aldeyra Therapeutics, Inc. (ALDX)
ALDX moved a median of +0.03% 30 minutes after news, and +0.52% by the close. How ALDX actually reacts to news — the realized, point-in-time move the market made, measured across 774 labeled events over the last three years with zero look-ahead.
ALDX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 47% | 772 |
| 30-min | +0.03% | 52% | 773 |
| 60-min | +0.28% | 52% | 773 |
| to close | +0.52% | 53% | 768 |
| Middle 50% of ALDX reactions | -1.06% to +1.29% |
|---|---|
| Median reaction (30-min) | +0.03% |
| Measured reactions | 774 |
Half of all Aldeyra Therapeutics, Inc. news events land between -1.06% and +1.29% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ALDX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 11 | 0.00% | 46% | +0.48% |
| Rating reiterations | 22 | +1.72% | 91% | +10.28% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how ALDX ranks against every other measured name →
That’s how ALDX usually reacts — get an email when it moves on news →Email me when ALDX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ALDX's baseline. Nothing else.
Recent ALDX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.30% | +0.19% | |
| Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.51% | -1.54% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.10% | +0.79% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.76% | +3.27% | |
| Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease | Press release | Business Wire | +2.56% | +12.82% | |
| Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.38% | +0.76% | |
| Form 8-K Aldeyra Therapeutics, For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | +2.56% | +12.82% | |
| Aldeyra Therapeutics to Host Regulatory Update Webcast | Press release | Business Wire | +2.56% | +12.82% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | -5.79% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.00% | +1.09% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.17% | -0.88% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.00% | -0.72% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.34% | -1.68% | |
| Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | +4.76% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.34% | +1.36% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -1.34% | -1.33% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -0.33% | +1.97% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.49% | -0.65% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.25% | -0.08% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.65% | — | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.00% | +1.60% | |
| Form 10-Q Aldeyra Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.64% | -0.64% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.33% | +1.64% | |
| Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.55% | -1.84% | |
| Form 8-K Aldeyra Therapeutics, For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | -0.62% | -4.94% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.98% | +3.60% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.88% | +0.00% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.86% | -0.86% | |
| Form 8-K Aldeyra Therapeutics, For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | -10.05% | -6.52% | |
| Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.26% | -0.77% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -3.69% | -4.93% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.72% | +10.84% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.87% | -2.62% | |
| Levicept Appoints Darlene Deptula-Hicks as CFO | Press release | GlobeNewswire | -2.41% | -2.19% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.89% | +1.33% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -2.90% | -6.00% | |
| Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.81% | +11.41% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.10% | -4.04% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.00% | +0.85% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.25% | -2.76% | |
| Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.30% | +3.01% | |
| Form 8-K Aldeyra Therapeutics, For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | +0.58% | -1.17% | |
| Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors | Press release | Business Wire | +0.58% | -1.17% | |
| Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference | Press release | Business Wire | -1.51% | -1.21% | |
| Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX | Press release | PR Newswire | -1.14% | -2.29% | |
| Form 10-Q Aldeyra Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.53% | +1.76% | |
| Form 8-K Aldeyra Therapeutics, For: May 01 | SEC filing · Form 8-K | SEC EDGAR | -0.28% | +2.62% | |
| REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026 | Press release | GlobeNewswire | +0.01% | +4.61% | |
| Form ARS Aldeyra Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.90% | -0.63% | |
| Form DEF 14A Aldeyra Therapeutics, For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | +1.90% | -0.63% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ALDX section they belong to.
Where else ALDX is measured.
ALDX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| HEMISPHERX BIOPHARMA (HEB) | 779 | -0.06% | 42% |
| TETRAPHASE PHARMACEUTICALS INC (TTPH) | 777 | -0.09% | 47% |
| CYTORI THERAPEUTICS (CYTX) | 774 | -0.72% | 32% |
| Adamis Pharmaceuticals Corporation (ADMP) | 772 | -0.47% | 40% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Aldeyra Therapeutics, Inc.'s median reaction calculated?
Every labeled ALDX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 774 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of ALDX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ALDX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.